A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants
NCT06511973 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42
Last updated 2024-09-19
Summary
Researchers are looking for a better way to treat muscle and joint pains. Researchers have seen that medicines which help reduce pain and inflammation could be safer when applied directly to the skin, called topical application, than when taken by mouth. However, recent studies have found that using these medications on the skin can sometimes cause skin reactions such as redness, itching, or irritation in the area where the medication is applied.
BAYH006689 topical gel is under development for the treatment of muscle and joint pains.
In this study, participants will be healthy and will not benefit from BAYH006689. However, the study will provide information about how to test BAYH006689 in future studies with people who have muscle and joint pain.
The main purpose of this study is to check whether BAYH006689 topical gel causes any irritation to the skin in healthy participants using a patch test called cumulative irritant patch test design. To do this, researchers will apply gel to participants' skin once a day for 21 days. Skin reactions will be assessed using a scale which will provide a score for redness, swelling, and other signs of skin irritation.
In this study, researchers will randomly assign 4 sites adjacent to each other, on the back of the participants' bodies just below the shoulder blades.
The following treatment gels will be applied using a patch.
* BAYH006689
* Placebo, which looks like the study drug, but does not have any medicine in it.
* 0.2% sodium lauryl sulfate (is a common ingredient in personal care products and when in contact with skin it could cause some skin irritation)
* 0.9% saline
Each participant will be in this study for 22 days, which includes:
* a visit to the clinic within 21 days of the study start, to confirm if the participant can take part in the study.
* participants will receive their assigned treatment gels at the identified skin site for 21 days.
* an end of study visit on Day 22, during which the researchers will remove the designed patches and assess any signs of skin irritation.
During the study, the doctors and their study team will:
* do physical examinations
* check participants' health by performing urine tests
* ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Conditions
- Pain
- Healthy Volunteers
Interventions
- DRUG
-
Naproxen (BAYH006689)
BAYH006689 gel will be dispensed directly on the patch
- DRUG
-
Placebo Gel
Placebo gel will be dispensed directly on the patch
- DRUG
-
A solution of 0.9% Saline
0.9% Saline will be dispensed directly on the patch
- DRUG
-
A solution of 0.2% SLS
0.2% SLS will be dispensed directly on the patch.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-07-23
- Primary Completion
- 2024-08-20
- Completion
- 2024-08-20
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations
NCT00665743 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
NCT00969449 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily
NCT02549469 ·Status: COMPLETED ·Phase: PHASE1
-
Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination
NCT01666678 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Trial of Naproxen Sodium/ Diphenhydramine
NCT01365052 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
NCT00621881 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects
NCT03396250 ·Status: COMPLETED ·Phase: PHASE1
-
Naproxen Sodium ER Pharmacokinetic Study
NCT00818415 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults
NCT04139824 ·Status: COMPLETED ·Phase: PHASE1
-
Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
NCT00966641 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Self Selection Trial of Naproxen Sodium
NCT01383486 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
NCT00170898 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis
NCT02183038 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium
NCT02201238 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
NCT00749385 ·Status: COMPLETED ·Phase: PHASE1
-
Naproxen for Pain Control With Intrauterine Device Insertion
NCT02388191 ·Status: COMPLETED ·Phase: NA
-
Changes in mRNA Expression Following Exposure to Naproxen
NCT01090596 ·Status: COMPLETED ·Phase: NA
-
A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions
NCT03424135 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone
NCT00992381 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fasting Conditions
NCT01131728 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults
NCT01889173 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of OXP005 to Assess Gastroduodenal Irritation
NCT02408978 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel
NCT01202799 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function
NCT00674856 ·Status: COMPLETED ·Phase: PHASE1
-
Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study
NCT03167541 ·Status: COMPLETED ·Phase: PHASE1